Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash & Equivalents (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Cash & Equivalents for 11 consecutive years, with $64.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 45.07% to $64.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $64.8 million through Dec 2025, up 45.07% year-over-year, with the annual reading at $64.8 million for FY2025, 45.07% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $64.8 million at Niagen Bioscience, up from $64.3 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $64.8 million in Q4 2025, with the low at $13.3 million in Q3 2022.
  • Average Cash & Equivalents over 5 years is $34.9 million, with a median of $28.1 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents surged 228.48% in 2021, then crashed 59.94% in 2022.
  • Over 5 years, Cash & Equivalents stood at $28.2 million in 2021, then decreased by 27.56% to $20.4 million in 2022, then skyrocketed by 33.68% to $27.3 million in 2023, then surged by 63.44% to $44.7 million in 2024, then surged by 45.07% to $64.8 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $64.8 million, $64.3 million, and $60.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.